The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Daniel G. Wolle - JPMorgan Chase & Co, Research Division - Analyst
: A couple for me. First, with a little bit of over 1 month of commercial launch behind us, what can you tell us about the initial activities that would
indicate that significant uptake is still an expectation for KORSUVA Injection? And I have a follow-up.
Question: Daniel G. Wolle - JPMorgan Chase & Co, Research Division - Analyst
: Okay, great. And in terms of activating and engaging these patients, is it possible for you to quantify for us the potential contribution to the
addressable patient population that can be driven by raising this patient awareness?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 09, 2022 / 8:30PM, CARA.OQ - Q1 2022 Cara Therapeutics Inc Earnings Call
Question: Daniel G. Wolle - JPMorgan Chase & Co, Research Division - Analyst
: Okay, great. And then on the European launch, can you provide us some color on how we should think about that your launch for Kapruvia, the
reimbursement dynamics across different countries and then the economics involved with the JV?
Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst
: The first is on the launch and the second is a clarification. First, it's good to hear that your partners launch is tracking per your expectations. It's still
early days. You have reimbursement. But has there been any nitpicks or pushback against the use of KORSUVA IV? What have those been if at all?
Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst
: Understood. And then the clarification. You mentioned the inventory dynamics, the way they work in dialysis clinics. So I just wanted to clarify that
on the $4.8 million of commercial supply revenue, that shipment was close to actual pull-through demand?
Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst
: The question was the $4.8 million, how does that ship in recognition work relative to the actual pull-through demand?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 09, 2022 / 8:30PM, CARA.OQ - Q1 2022 Cara Therapeutics Inc Earnings Call
Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst
: Let me ask that in another way then. Roughly how many months of usage would that correspond to then?
| 
